Treatment of olaparib-resistant ovarian cancer cell line with napabucasin, the STAT3 inhibitor, down-regulated the STAT3 downstream genes, disturbed tumor progression, and improved PARPi sensitivity [116]. The gene discussed is STAT3; the disease is ovarian carcinoma.